Prevalence and management of castration-resistant prostate cancer of unknown metastatic status in the real-world setting: The AfroDiTA study

Miguel Rodrigo-Aliaga ¹, José L Alvarez-Ossorio ², Andrés Rodríguez-Alonso ³

⁰University General Hospital of Castellón, Castellón, Spain.

Urologic Oncology +

|

September 22, 2024

View abstract on PubMed

Summary

This study found that many prostate cancer patients with unknown metastatic status (CRPC-MX) lack proper follow-up. Identifying these patients improved physician awareness and adherence to guidelines, leading to better prostate cancer care.

Area Of Science

Oncology
Urology
Real-world evidence studies

Background

Early detection of metastases in prostate cancer (PC) is critical for patient management.
Castration-resistant prostate cancer with unknown metastatic status (CRPC-MX) represents a challenge in clinical practice.
Understanding the characteristics and management of CRPC-MX patients is essential for improving outcomes.

Purpose Of The Study

To describe the non-pharmacological management of CRPC-MX patients.
To characterize patients with CRPC-MX.
To estimate the prevalence of CRPC-MX in Spain.

Main Methods

A cross-sectional, multicenter, real-world study was conducted.
Adult CRPC-MX patients were identified using a validated algorithm across 46 urology services.
Patients were assessed in two phases, 15 months apart, to evaluate changes in management and classification.

Main Results

Approximately 4.8% of eligible PC patients were initially classified as CRPC-MX.
A significant proportion of CRPC-MX patients lacked histological diagnosis and curative intent treatment.
Identification of CRPC-MX led to improved follow-up, including increased PSA testing, imaging, and specialist consultations.

Conclusions

A considerable number of PC patients on androgen deprivation therapy (ADT) receive inadequate follow-up in real-world settings.
The identification of CRPC-MX patients heightened physician awareness and improved guideline adherence.
Improved management following CRPC-MX identification resulted in enhanced care for these prostate cancer patients.

Keywords:

Castration-resistant prostate cancer Imaging Metastasis Patient care management Prostate cancer